Research area
Growth hormone axis
Compounds that act on growth hormone release, either directly or through the ghrelin/GHRH signaling pathways -- studied for effects on growth hormone levels, body composition, and recovery.
15 entries in this category.
-
CJC-1295 (no DAC)
The product sold as CJC-1295 without DAC is a different molecule from CJC-1295: 29 residues instead of 30, 279 daltons lighter, with none of the albumin-binding chemistry that defined the original. No human study of it exists, its half-life has never been measured, and the paper used to justify choosing it studied the other molecule.
-
CJC-1295 / Ipamorelin
CJC-1295 / ipamorelin is a name applied to vials that differ from one another in total weight, in split and in which CJC-1295 they contain. Fourteen listings were examined and one of them, a 15 mg vial, discloses no split at all. The combination has never been given to a human being in a registered trial.
-
CJC-1295 with DAC
CJC-1295 is a GHRH analogue whose defining feature is a group that binds covalently to albumin, giving it a half-life of days rather than minutes. Its human record is four studies in healthy volunteers, and its only registered trial was terminated in 2006 after a participant death and has never reported results.
-
FLGR242
FLGR242 is a seller-named follistatin construct with no published study. What the patent, the follistatin literature and the registries show.
* Also filed under: Tissue repair and recovery
-
Follistatin 344
Also relevant to tissue repair and recovery research. Follistatin 344 is a myostatin-binding protein isoform studied mainly through AAV gene-therapy trials for muscular dystrophy, not as the injected protein sold under this name by research-chemical vendors, which has no human safety or dosing data.
* Also filed under: Tissue repair and recovery
-
GHRP-2
GHRP-2 (pralmorelin) is a synthetic growth-hormone-releasing peptide approved in Japan only as a diagnostic test for growth hormone deficiency. Community dosing figures of 100-300 mcg circulate widely online but are not traceable to a validated clinical protocol.
-
GHRP-6
GHRP-6 is one of the original growth hormone releasing peptides, known for strongly stimulating both growth hormone release and appetite. It has never been approved as a medicine, and the 100-300 mcg community dosing figures that circulate online are not traceable to a validated clinical protocol.
-
Hexarelin
Hexarelin (examorelin) is a potent growth-hormone-releasing peptide that reached Phase II clinical trials for growth hormone deficiency and heart failure before development was discontinued. It was never approved; community dosing figures of 100-200 mcg circulate online without a verified clinical source.
-
IGF-1 DES
Quick answer: IGF-1 DES (des(1-3)IGF-1) is a truncated, 67-amino-acid variant of insulin-like growth factor 1 missing the first three N-terminal residues. That deletion sharply reduces its binding to IGF-binding proteins (IGFBPs), leaving more of the molecule free to act on the IGF-1 receptor and making it roughly 4 to 10 times more potent than intact ... <a title="Tesamorelin / Ipamorelin" class="read-more" href="https://peptideblog.net/blends/tesamorelin-ipamorelin/" aria-label="Read more about Tesamorelin / Ipamorelin">Read more</a>
-
IGF-1 LR3
IGF-1 LR3 is a lab-engineered, long-acting analog of IGF-1 originally built as a cell-culture research reagent. It has never undergone human clinical trials; the 20-50 mcg/day figures circulating in bodybuilding communities are unverified and not clinically sourced.
-
Ipamorelin
Ipamorelin is a pentapeptide growth hormone secretagogue that was developed properly and did not make it: two phase 2 trials, one that missed its endpoint and one that has never reported. Its selectivity claim rests on a single 1998 pig experiment, and the advisory committee voted unanimously against it in 2024.
-
MK-677
MK-677 (ibutamoren) is an oral, non-peptide growth hormone secretagogue with real published human trial data, including a two-year study in older adults. It has never been approved as a drug; the widely used 25 mg daily community dose overlaps with an actual clinical trial dose, but unsupervised use lacks the monitoring that trial included.
-
Sermorelin
Sermorelin is a GHRH(1-29) analogue that was FDA-approved (Geref, 1997) for pediatric growth hormone deficiency and voluntarily withdrawn commercially in 2008 for business reasons, not safety. It is not currently FDA-approved for any use and is now most commonly used off-label in adults through compounding pharmacies, without a dedicated modern trial establishing that use.
-
Tesamorelin
Tesamorelin is an approved prescription drug, and its label covers one thing: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label states it is not indicated for weight loss management. Its European application was withdrawn after the regulator provisionally found no demonstrated clinical benefit despite the measured fat reduction.
-
Tesamorelin / Ipamorelin
Tesamorelin / ipamorelin pairs an FDA-approved GHRH analogue with an unapproved ghrelin-receptor agonist. An FDA warning letter documents one marketed version, 10 mg tesamorelin to 3 mg ipamorelin. The combination has never been tested in a trial, and the tesamorelin dose that circulates for it is the same dose that failed to separate from placebo in tesamorelin's own dose-ranging study.